Location & dates EMBL Heidelberg, Germany 14 - 17 Jun 2017
Deadlines Registration closed Abstract submission closed
EES_logo

Coronavirus information for participants

The onsite course and conference programme at EMBL has been paused until the end of June 2020.


We aim to continue offering our advanced training for the scientific community however we safely can. While some events have been cancelled, many have been rescheduled for a later date and others will be delivered as virtual events.


Registration is open for onsite courses and conferences starting after 1 July and for the virtual events. All registration fees for any events which don’t take place due to the COVID-19 disruption are fully refundable.


More information for participants of events at EMBL Heidelberg can be found here.

Stay up to date! Add this event easily to your calendar by downloading the iCal>>     Addtocalendar

Topics

  • Genetics: From Gene To Function
  • Innate Immunity and Related Mechanisms
  • Cellular and Molecular Mechanisms
  • Proteases in Neurodegeneration
  • Biomarkers & Clinical Research
  • Special Session on Animal models

Why attend?

This symposium will focus on the molecular basis of major neurodegenerative diseases such as Alzheimer’s Disease, Parkinson’s Disease, Huntington’s Disease, Frontotemporal Lobar Degeneration and Amyotrophic Lateral Sclerosis, with a strong emphasis on mechanism based drug development. The meeting will cover the various molecular mechanisms linked to these diseases, including RNA biology, nuclear transport, protein processing, protein aggregation and protein folding. The symposium will also address the genetic components underlying neurodegeneration and the involvement of innate immune responses, discuss disease biomarkers and therapeutic options, as well as using animal models for studying neurodegenerative disease.

Aims

The aim of the meeting is to promote discussions and sharing of new findings among basic scientists, clinical researchers, and their counterparts from pharmaceutical industry, in order to advance our understanding of neurodegeneration and to further drug development in an area urgently requiring therapeutic progress.